APLS
Apellis Pharmaceuticals, Inc.
Biotechnology
Market Cap$5.25B
5Y Perf.-28.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
APLS vs BCAB vs BEAM vs REGN
Revenue, margins, valuation, and 5-year total return — side by side.
BCAB
BioAtla, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-99.7%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.-61.5%
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+46.8%
APLS vs BCAB vs BEAM vs REGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | APLS | BCAB | BEAM | REGN |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5.25B | $5M | $3.23B | $73.68B |
| Revenue (TTM) | $1.03B | $2M | $132M | $14.92B |
| Net Income (TTM) | $133M | $-60M | $-65M | $4.42B |
| Gross Margin | 89.4% | 100.0% | -64.2% | 84.5% |
| Operating Margin | 16.1% | -29.7% | -281.0% | 24.3% |
| Forward P/E | 227.8x | — | — | 15.3x |
| Total Debt | $486M | $6M | $294M | $2.71B |
| Cash & Equiv. | $468M | $7M | $295M | $3.12B |
APLS vs BCAB vs BEAM vs REGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
APLS
BCAB
BEAM
REGN
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Apellis Pharmaceuti… (APLS) | 100 | 71.7 | -28.3% |
| BioAtla, Inc. (BCAB) | 100 | 0.3 | -99.7% |
| Beam Therapeutics I… (BEAM) | 100 | 38.5 | -61.5% |
| Regeneron Pharmaceu… (REGN) | 100 | 146.8 | +46.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: APLS vs BCAB vs BEAM vs REGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Apellis Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. BCAB and BEAM also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
APLS
Apellis Pharmaceuticals, Inc.
The Growth Play
APLS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 28.5%, EPS growth 111.3%, 3Y rev CAGR 137.0%
- 192.3% 10Y total return vs REGN's 90.0%
- +128.0% vs BCAB's -80.6%
- 13.2% ROA vs BCAB's -250.6%
Best for: growth exposure and long-term compounding
BCAB
BioAtla, Inc.
The Income Pick
BCAB is the clearest fit if your priority is income & stability.
- beta 0.51
- Beta 0.51 vs BEAM's 2.14
Best for: income & stability
BEAM
Beam Therapeutics Inc.
The Growth Leader
BEAM is the clearest fit if your priority is growth.
- 120.0% revenue growth vs BCAB's -81.8%
Best for: growth
REGN
Regeneron Pharmaceuticals, Inc.
The Defensive Pick
REGN carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.81, Low D/E 8.7%, current ratio 4.13x
- Beta 0.81, yield 0.5%, current ratio 4.13x
- Better valuation composite
- 29.6% margin vs BCAB's -29.8%
Best for: sleep-well-at-night and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs BCAB's -81.8% |
| Value | REGN | Better valuation composite |
| Quality / Margins | REGN | 29.6% margin vs BCAB's -29.8% |
| Stability / Safety | BCAB | Beta 0.51 vs BEAM's 2.14 |
| Dividends | REGN | 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | APLS | +128.0% vs BCAB's -80.6% |
| Efficiency (ROA) | APLS | 13.2% ROA vs BCAB's -250.6% |
APLS vs BCAB vs BEAM vs REGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
Segment breakdown not available.
FY 2025
APLS vs BCAB vs BEAM vs REGN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGBEAM
Who Leads Where
REGN leads in 2 of 6 categories
APLS leads 0 • BCAB leads 0 • BEAM leads 0 • 3 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
BCABBioAtla, Inc.
0leads
APLSApellis Pharmaceutica…
0leads
REGNRegeneron Pharmaceuti…
2leads
6 Total Categories
CATEGORYLEADERvs APLSvs BCABMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
REGN4/6
Valuation MetricsMultiples, price ratios, and targets
REGN3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
REGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN is the larger business by revenue, generating $14.9B annually — 7459.8x BCAB's $2M. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to BCAB's -29.8%. On growth, REGN holds the edge at +19.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.0B | $2M | $132M | $14.9B |
| EBITDAEarnings before interest/tax | $166M | -$59M | -$355M | $4.2B |
| Net IncomeAfter-tax profit | $133M | -$60M | -$65M | $4.4B |
| Free Cash FlowCash after capex | $38M | -$34M | -$384M | $4.2B |
| Gross MarginGross profit ÷ Revenue | +89.4% | +100.0% | -64.2% | +84.5% |
| Operating MarginEBIT ÷ Revenue | +16.1% | -29.7% | -2.8% | +24.3% |
| Net MarginNet income ÷ Revenue | +13.0% | -29.8% | -49.2% | +29.6% |
| FCF MarginFCF ÷ Revenue | +3.7% | -17.0% | -2.9% | +27.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.1% | — | -100.0% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | +46.7% | +26.6% | -7.2% |
REGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
REGN leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 17.1x trailing earnings, REGN trades at a 92% valuation discount to APLS's 227.8x P/E. On an enterprise value basis, REGN's 17.8x EV/EBITDA is more attractive than APLS's 92.5x.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Market CapShares × price | $5.3B | $5M | $3.2B | $73.7B |
| Enterprise ValueMkt cap + debt − cash | $5.3B | $4M | $3.2B | $73.3B |
| Trailing P/EPrice ÷ TTM EPS | 227.83x | -0.09x | -38.85x | 17.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 15.35x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.70x |
| EV / EBITDAEnterprise value multiple | 92.46x | — | — | 17.78x |
| Price / SalesMarket cap ÷ Revenue | 5.23x | 2.56x | 23.14x | 5.14x |
| Price / BookPrice ÷ Book value/share | 13.96x | — | 2.51x | 2.46x |
| Price / FCFMarket cap ÷ FCF | 116.63x | — | — | 18.06x |
REGN leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — APLS and REGN each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
APLS delivers a 39.7% return on equity — every $100 of shareholder capital generates $40 in annual profit, vs $-6 for BEAM. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to APLS's 1.31x. On the Piotroski fundamental quality scale (0–9), APLS scores 7/9 vs BCAB's 2/9, reflecting strong financial health.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +39.7% | — | -5.9% | +14.3% |
| ROA (TTM)Return on assets | +13.2% | -2.5% | -4.6% | +11.1% |
| ROICReturn on invested capital | +12.3% | — | -31.1% | +8.9% |
| ROCEReturn on capital employed | +7.6% | -4.0% | -33.3% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 | 4 | 5 |
| Debt / EquityFinancial leverage | 1.31x | — | 0.24x | 0.09x |
| Net DebtTotal debt minus cash | $19M | -$918,000 | -$1M | -$412M |
| Cash & Equiv.Liquid assets | $468M | $7M | $295M | $3.1B |
| Total DebtShort + long-term debt | $486M | $6M | $294M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 6.50x | — | 1.08x | 108.44x |
Evenly matched — APLS and REGN each lead in 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — APLS and REGN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in REGN five years ago would be worth $14,365 today (with dividends reinvested), compared to $19 for BCAB. Over the past 12 months, APLS leads with a +128.0% total return vs BCAB's -80.6%. The 3-year compound annual growth rate (CAGR) favors REGN at -1.7% vs BCAB's -70.1% — a key indicator of consistent wealth creation.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +58.6% | -83.7% | +16.0% | -8.5% |
| 1-Year ReturnPast 12 months | +128.0% | -80.6% | +93.9% | +27.1% |
| 3-Year ReturnCumulative with dividends | -55.1% | -97.3% | -5.6% | -5.1% |
| 5-Year ReturnCumulative with dividends | -12.9% | -99.8% | -55.6% | +43.6% |
| 10-Year ReturnCumulative with dividends | +192.3% | -99.7% | +67.8% | +90.0% |
| CAGR (3Y)Annualised 3-year return | -23.4% | -70.1% | -1.9% | -1.7% |
Evenly matched — APLS and REGN each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — APLS and BCAB each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCAB is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than BEAM's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. APLS currently trades 99.7% from its 52-week high vs BCAB's 6.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.06x | 0.51x | 2.14x | 0.81x |
| 52-Week HighHighest price in past year | $41.12 | $71.50 | $36.44 | $821.11 |
| 52-Week LowLowest price in past year | $16.10 | $0.33 | $15.35 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +99.7% | +6.1% | +86.4% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 87.2 | 40.5 | 60.9 | 44.9 |
| Avg Volume (50D)Average daily shares traded | 5.4M | 40K | 2.0M | 631K |
Evenly matched — APLS and BCAB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: APLS as "Buy", BCAB as "Buy", BEAM as "Buy", REGN as "Buy". Consensus price targets imply 5647.1% upside for BCAB (target: $250) vs -24.4% for APLS (target: $31). REGN is the only dividend payer here at 0.48% yield — a key consideration for income-focused portfolios.
| Metric | APLSApellis Pharmaceu… | BCABBioAtla, Inc. | BEAMBeam Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $31.00 | $250.00 | $40.83 | $865.68 |
| # AnalystsCovering analysts | 25 | 9 | 27 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +5.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
REGN leads in 2 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 3 categories are tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 2 of 6 categories
Loading custom metrics...
APLS vs BCAB vs BEAM vs REGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is APLS or BCAB or BEAM or REGN a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -81. 8% for BioAtla, Inc. (BCAB). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Apellis Pharmaceuticals, Inc. (APLS) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — APLS or BCAB or BEAM or REGN?
On trailing P/E, Regeneron Pharmaceuticals, Inc.
(REGN) is the cheapest at 17. 1x versus Apellis Pharmaceuticals, Inc. at 227. 8x.
03Which is the better long-term investment — APLS or BCAB or BEAM or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc.
(REGN) delivered a total return of +43. 6%, compared to -99. 8% for BioAtla, Inc. (BCAB). Over 10 years, the gap is even starker: APLS returned +192. 3% versus BCAB's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — APLS or BCAB or BEAM or REGN?
By beta (market sensitivity over 5 years), BioAtla, Inc.
(BCAB) is the lower-risk stock at 0. 51β versus Beam Therapeutics Inc. 's 2. 14β — meaning BEAM is approximately 320% more volatile than BCAB relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 131% for Apellis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — APLS or BCAB or BEAM or REGN?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -81. 8% for BioAtla, Inc. (BCAB). On earnings-per-share growth, the picture is similar: Apellis Pharmaceuticals, Inc. grew EPS 111. 3% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, APLS leads at 137. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — APLS or BCAB or BEAM or REGN?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -29. 8% for BioAtla, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -29. 7% for BCAB. At the gross margin level — before operating expenses — BCAB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is APLS or BCAB or BEAM or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for BCAB: 5647.
1% to $250. 00.
08Which pays a better dividend — APLS or BCAB or BEAM or REGN?
In this comparison, REGN (0.
5% yield) pays a dividend. APLS, BCAB, BEAM do not pay a meaningful dividend and should not be held primarily for income.
09Is APLS or BCAB or BEAM or REGN better for a retirement portfolio?
For long-horizon retirement investors, BioAtla, Inc.
(BCAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51)). Beam Therapeutics Inc. (BEAM) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCAB: -99. 7%, BEAM: +67. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between APLS and BCAB and BEAM and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: APLS is a small-cap high-growth stock; BCAB is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(APLS: 15.1% · BCAB: -81.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.